Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | AVPR1B | P47901 | 6/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.39 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11931998 | 0.91 | HRH3 (0.39) | HRH3HTR4ALDH1A1SMN1; SMN2SRC | |
| SCHEMBL12944924 | 0.89 | HRH3 (0.40) | HRH3HTR4ALDH1A1SMN1; SMN2SRC | |
| SCHEMBL4514195 | 0.85 | ADORA3 (0.48) | ADORA3 | |
| SCHEMBL4511334 | 0.81 | ADORA3 (0.49) | ADORA3 | |
| SCHEMBL7368048 | 0.76 | KDM4E (0.43) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL13936980 | 0.76 | KMO (0.39) | ADORA3 | |
| SCHEMBL8142255 | 0.72 | BCHE (0.42) | BCHEHRH3HTR4ALDH1A1SMN1; SMN2 | |
| SCHEMBL4491278 | 0.69 | HRH3 (0.46) | AVPR1BHRH3 | |
| SCHEMBL8142869 | 0.69 | HRH3 (0.39) | BCHEHRH3HTR4ALDH1A1SMN1; SMN2 | |
| SCHEMBL13936982 | 0.68 | ADORA3 (0.48) | ADORA3ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3485881-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | President and Fellows of Harvard College (US) | 2019-05-22 | — | — | EP | disclosed |